Goldman Sachs Group Inc. Has $7.89 Million Holdings in BioLife Solutions, Inc. $BLFS

Key Points

• Goldman Sachs Group Inc. reduced its stake in BioLife Solutions by 8.6%, selling 32,600 shares during the 1st quarter, now owning about 0.73% of the company.
• BioLife Solutions reported an earnings miss with an EPS of ($0.33), significantly lower than the consensus estimate of ($0.02), despite revenue exceeding expectations at $25.42 million.
• Multiple analysts have varying recommendations on BioLife Solutions, with Zacks upgrading it to a "strong-buy" and HC Wainwright raising their price target to $32.00.

Goldman Sachs Group Inc. cut its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 8.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 345,548 shares of the medical equipment provider's stock after selling 32,600 shares during the quarter. Goldman Sachs Group Inc. owned about 0.73% of BioLife Solutions worth $7,892,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of BLFS. Northern Trust Corp grew its holdings in BioLife Solutions by 7.9% in the fourth quarter. Northern Trust Corp now owns 411,033 shares of the medical equipment provider's stock worth $10,670,000 after purchasing an additional 30,217 shares during the period. Deutsche Bank AG lifted its position in shares of BioLife Solutions by 49.8% during the fourth quarter. Deutsche Bank AG now owns 31,171 shares of the medical equipment provider's stock valued at $809,000 after purchasing an additional 10,368 shares in the last quarter. Graham Capital Management L.P. bought a new stake in BioLife Solutions in the fourth quarter worth about $254,000. Gotham Asset Management LLC raised its position in BioLife Solutions by 11.5% in the fourth quarter. Gotham Asset Management LLC now owns 13,800 shares of the medical equipment provider's stock worth $358,000 after acquiring an additional 1,426 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of BioLife Solutions by 5.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,508 shares of the medical equipment provider's stock worth $532,000 after purchasing an additional 1,047 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of BioLife Solutions stock in a transaction on Friday, August 15th. The stock was sold at an average price of $24.40, for a total value of $12,200,000.00. Following the transaction, the insider directly owned 6,707,165 shares in the company, valued at $163,654,826. The trade was a 6.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Troy Wichterman sold 1,032 shares of BioLife Solutions stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $26.83, for a total value of $27,688.56. Following the transaction, the chief financial officer owned 184,186 shares in the company, valued at $4,941,710.38. This represents a 0.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,019,198 shares of company stock worth $23,981,317 in the last 90 days. 2.20% of the stock is owned by corporate insiders.

BioLife Solutions Trading Down 1.8%

BLFS traded down $0.48 on Friday, hitting $25.80. The company had a trading volume of 105,413 shares, compared to its average volume of 473,736. The firm has a market cap of $1.24 billion, a P/E ratio of -214.86 and a beta of 1.78. BioLife Solutions, Inc. has a 1 year low of $19.10 and a 1 year high of $29.55. The company's fifty day moving average price is $23.76 and its 200 day moving average price is $23.35.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The firm had revenue of $25.42 million during the quarter, compared to analysts' expectations of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. On average, analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Analyst Ratings Changes

BLFS has been the subject of several recent analyst reports. Stephens started coverage on shares of BioLife Solutions in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Finally, Zacks Research upgraded shares of BioLife Solutions to a "strong-buy" rating in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $31.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.